MLICM
ITOS

Metropolitan Life Insurance Company (MetLife)’s iTeos Therapeutics ITOS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,365
Closed -$18.6K – 1068
2024
Q1 		$18.6K Hold
1,365
– – ﹤0.01% 1894
2023
Q4 		$14.9K Hold
1,365
– – ﹤0.01% 2040
2023
Q3 		$14.9K Hold
1,365
– – ﹤0.01% 2030
2023
Q2 		$18.1K Hold
1,365
– – ﹤0.01% 1988
2023
Q1 		$18.6K Hold
1,365
– – ﹤0.01% 1921
2022
Q4 		$26.7K Hold
1,365
– – ﹤0.01% 1846
2022
Q3 		$26K Hold
1,365
– – ﹤0.01% 1877
2022
Q2 		$28.1K Hold
1,365
– – ﹤0.01% 1862
2022
Q1 		$43.9K Sell
1,365
-4,679
-77% -$170K ﹤0.01% 1670
2021
Q4 		$281K Hold
6,044
– – ﹤0.01% 1779
2021
Q3 		$163K Sell
6,044
-610
-9% -$15.9K ﹤0.01% 2229
2021
Q2 		$171K Buy
6,654
+808
+14% +$19.3K ﹤0.01% 2267
2021
Q1 		$200K Buy
5,846
+2,439
+72% +$88.1K ﹤0.01% 2020
2020
Q4 		$115K Hold
3,407
– – ﹤0.01% 2292
2020
Q3 		$84.1K Buy
+3,407
New +$91.6K ﹤0.01% 2311

Other funds holding ITOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ITOS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of iTeos Therapeutics (ITOS) in Q2 2024, closing a stake of 1,365 shares — an estimated $18.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ITOS in Q3 2020 and held it in 15 quarters. The position peaked at $281K in Q4 2021. 138 funds tracked by Wall St. Rank hold ITOS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining iTeos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,365 iTeos Therapeutics shares in Q2 2024, an estimated $18.6K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in iTeos Therapeutics in Q3 2020 and held it in 15 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s iTeos Therapeutics position peaked at $281K in Q4 2021.
  • 138 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.